Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of oxymetazoline hydrochloride eye drops in Chinese adults with acquired blepharoptosis
CTR20242719Phase 3Active
- Sponsor
- Nanjing Hengdao Pharmaceutical Technology
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of oxymetazoline in acquired blepharoptosis, sponsored by Nanjing Hengdao Pharmaceutical Technology. Started Oct 2024; status: active.
02
Drugs
oxymetazoline
03
Conditions
acquired blepharoptosis
Beyond the preview
Go deeper on CTR20242719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242719.